nach oben

Current HIV/AIDS Reports

Erschienen in:

01.02.2020 | HIV Pathogenesis and Treatment (AL Landay and NS Utay, Section Editors)

Recent Advances in the Development of Integrase Inhibitors for HIV Treatment

verfasst von: Jay Trivedi, Dinesh Mahajan, Russell J. Jaffe, Arpan Acharya, Debashis Mitra, Siddappa N. Byrareddy

Erschienen in: Current HIV/AIDS Reports | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of the Review

The complex multistep life cycle of HIV allows it to proliferate within the host and integrate its genome in to the host chromosomal DNA. This provirus can remain dormant for an indefinite period. The process of integration, governed by integrase (IN), is highly conserved across the Retroviridae family. Hence, targeting integration is not only expected to block HIV replication but may also reveal new therapeutic strategies to treat HIV as well as other retrovirus infections.

Recent Findings

HIV integrase (IN) has gained attention as the most promising therapeutic target as there are no equivalent homologues of IN that has been discovered in humans. Although current nano-formulated long-acting IN inhibitors have demonstrated the phenomenal ability to block HIV integration and replication with extraordinary half-life, they also have certain limitations.

Summary

In this review, we have summarized the current literature on clinically established IN inhibitors, their mechanism of action, the advantages and disadvantages associated with their therapeutic application, and finally current HIV cure strategies using these inhibitors.

Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). 1983. Rev Investig Clin. 2004;56(2):126–9. https://doi.org/10.1126/science.6189183.CrossRef

Gallo RC, Sarin PS, Gelmann EP, Robert-Guroff M, Richardson E, Kalyanaraman VS, et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science. 1983;220(4599):865–7. https://doi.org/10.1126/science.6601823.CrossRefPubMed

Levy JA, Hoffman AD, Kramer SM, Landis JA, Shimabukuro JM, Oshiro LS. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science. 1984;225(4664):840–2. https://doi.org/10.1126/science.6206563.CrossRefPubMed

Prieto P, Podzamczer D. Switching strategies in the recent era of antiretroviral therapy. Expert Rev Clin Pharmacol. 2019;12(3):235–47. https://doi.org/10.1080/17512433.2019.1575728.CrossRefPubMed

Nanfack AJ, Redd AD, Bimela JS, Ncham G, Achem E, Banin AN, et al. Multimethod longitudinal HIV drug resistance analysis in antiretroviral-therapy-naive patients. J Clin Microbiol. 2017;55(9):2785–800. https://doi.org/10.1128/JCM.00634-17.CrossRefPubMedPubMedCentral

Schauer G, Sluis-Cremer N. HIV-1 resistance to reverse transcriptase inhibitors. In: Berghuis A, Matlashewski G, Wainberg MA, Sheppard D, editors. Handbook of antimicrobial resistance. New York: Springer New York; 2017. p. 523–42.CrossRef

Holmes M, Zhang F, Bieniasz PD. Single-cell and single-cycle analysis of HIV-1 replication. PLoS Pathog. 2015;11(6):e1004961. https://doi.org/10.1371/journal.ppat.1004961.CrossRefPubMedPubMedCentral

• Schott K, Konig R. Picking the Survivor! CRISPR Reveals HIV Dependency Factors. Trends Microbiol. 2017;25(4):243–5. https://doi.org/10.1016/j.tim.2017.02.004. This interesting study highlights three HIV dependency factors by utilisation of loss-of-function CRISPR/Cas9 technology. These HIV dependency factors are vital for virus replication cycle; their knock out attenuates virus replication even in primary cells without being lethal to cells. CrossRefPubMed

•• Engelman AN, Singh PK. Cellular and molecular mechanisms of HIV-1 integration targeting. Cell Mol Life Sci. 2018;75(14):2491–507. https://doi.org/10.1007/s00018-018-2772-5. Outstanding elaboration about the events that take place during integration of viral genome in to the "gene-rich" area of the chromosome. The review also briefs about the development of small molecules that block these events and ultimately hamper the virus replication cycle. CrossRefPubMedPubMedCentral

10.

• Hu H, Xiao A, Zhang S, Li Y, Shi X, Jiang T, et al. DeepHINT: understanding HIV-1 integration via deep learning with attention. Bioinformatics. 2019;35(10):1660–7. https://doi.org/10.1093/bioinformatics/bty842. Interesting new approach of attention based deep learning network, DeepHINT, that predicts the integration site of provirus into the host chromosome. CrossRefPubMed

11.

Koczor CA, Lewis W. Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA. Expert Opin Drug Metab Toxicol. 2010;6(12):1493–504. https://doi.org/10.1517/17425255.2010.526602.CrossRefPubMed

12.

Margolis AM, Heverling H, Pham PA, Stolbach A. A review of the toxicity of HIV medications. J Med Toxicol. 2014;10(1):26–39. https://doi.org/10.1007/s13181-013-0325-8.CrossRefPubMed

13.

Eron JJ Jr. HIV-1 protease inhibitors. Clin Infect Dis. 2000;30(Suppl 2):S160–70. https://doi.org/10.1086/313853.CrossRefPubMed

14.

Echecopar-Sabogal J, D'Angelo-Piaggio L, Chaname-Baca DM, Ugarte-Gil C. Association between the use of protease inhibitors in highly active antiretroviral therapy and incidence of diabetes mellitus and/or metabolic syndrome in HIV-infected patients: a systematic review and meta-analysis. Int J STD AIDS. 2018;29(5):443–52. https://doi.org/10.1177/0956462417732226.CrossRefPubMed

15.

Soriano V, Fernandez-Montero JV, Benitez-Gutierrez L, Mendoza C, Arias A, Barreiro P, et al. Dual antiretroviral therapy for HIV infection. Expert Opin Drug Saf. 2017;16(8):923–32. https://doi.org/10.1080/14740338.2017.1343300.CrossRefPubMed

16.

Engelman A, Cherepanov P. Retroviral Integrase structure and DNA recombination mechanism. Microbiol Spectr. 2014;2(6):1–22.CrossRef

17.

Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov. 2005;4(3):236–48. https://doi.org/10.1038/nrd1660.CrossRefPubMed

18.

Al-Mawsawi LQ, Al-Safi RI, Neamati N. Anti-infectives: clinical progress of HIV-1 integrase inhibitors. Expert Opin Emerg Drugs. 2008;13(2):213–25. https://doi.org/10.1517/14728214.13.2.213.CrossRefPubMed

19.

Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487(7408):482–5. https://doi.org/10.1038/nature11286.CrossRefPubMedPubMedCentral

20.

Coiras M, Lopez-Huertas MR, Perez-Olmeda M, Alcami J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol. 2009;7(11):798–812. https://doi.org/10.1038/nrmicro2223.CrossRefPubMed

21.

Chen JC, Krucinski J, Miercke LJ, Finer-Moore JS, Tang AH, Leavitt AD, et al. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc Natl Acad Sci U S A. 2000;97(15):8233–8. https://doi.org/10.1073/pnas.150220297.CrossRefPubMedPubMedCentral

22.

Yuan P, Gupta K, Van Duyne GD. Tetrameric structure of a serine integrase catalytic domain. Structure. 2008;16(8):1275–86. https://doi.org/10.1016/j.str.2008.04.018.CrossRefPubMed

23.

Engelman A, Cherepanov P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol. 2012;10(4):279–90. https://doi.org/10.1038/nrmicro2747.CrossRefPubMedPubMedCentral

24.

Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature. 2010;464(7286):232–6. https://doi.org/10.1038/nature08784.CrossRefPubMedPubMedCentral

25.

Kulkosky J, Jones KS, Katz RA, Mack JP, Skalka AM. Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. Mol Cell Biol. 1992;12(5):2331–8. https://doi.org/10.1128/mcb.12.5.2331.CrossRefPubMedPubMedCentral

26.

• Choi E, Mallareddy JR, Lu D, Kolluru S. Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase. Future Sci OA. 2018;4(9):Fso338. Interesting review about the development of novel small molecules that inhibit HIV-1 IN by targeting different sites of the enzyme which are less sensitive to point mutations. CrossRef

27.

Li X, Krishnan L, Cherepanov P, Engelman A. Structural biology of retroviral DNA integration. Virology. 2011;411(2):194–205. https://doi.org/10.1016/j.virol.2010.12.008.CrossRefPubMedPubMedCentral

28.

Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 2002;110(4):521–9. https://doi.org/10.1016/S0092-8674(02)00864-4.CrossRefPubMed

29.

Deeks ED. Raltegravir once-daily tablet: a review in HIV-1 infection. Drugs. 2017;77(16):1789–95.CrossRef

30.

Croxtall JD, Lyseng-Williamson KA, Perry CM. Raltegravir. Drugs. 2008;68(1):131–8. https://doi.org/10.2165/00003495-200868010-00009.CrossRefPubMed

31.

Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359(4):339–54. https://doi.org/10.1056/NEJMoa0708975.CrossRefPubMed

32.

Pace P, Di Francesco ME, Gardelli C, Harper S, Muraglia E, Nizi E, et al. Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors. J Med Chem. 2007;50(9):2225–39. https://doi.org/10.1021/jm070027u.CrossRefPubMed

33.

Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, Ferrara M, et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem. 2008;51(18):5843–55. https://doi.org/10.1021/jm800245z.CrossRefPubMed

34.

Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Benard A, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother. 2008;62(5):914–20. https://doi.org/10.1093/jac/dkn335.CrossRefPubMed

35.

Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46(2):125–33. https://doi.org/10.1097/QAI.0b013e318157131c.CrossRefPubMed

36.

Rockstroh JK, Lennox JL, Dejesus E, Saag MS, Lazzarin A, Wan H, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011;53(8):807–16. https://doi.org/10.1093/cid/cir510.CrossRefPubMed

37.

Serrao E, Odde S, Ramkumar K, Neamati N. Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology. 2009;6:25. https://doi.org/10.1186/1742-4690-6-25.CrossRefPubMedPubMedCentral

38.

Cocohoba J, Dong BJ. Raltegravir: the first HIV integrase inhibitor. Clin Ther. 2008;30(10):1747–65. https://doi.org/10.1097/QAI.0000000000002065.CrossRefPubMed

39.

Iwamoto M, Kassahun K, Troyer MD, Hanley WD, Lu P, Rhoton A, et al. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol. 2008;48(2):209–14. https://doi.org/10.1177/0091270007310382.CrossRefPubMed

40.

Wenning LA, Friedman EJ, Kost JT, Breidinger SA, Stek JE, Lasseter KC, et al. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother. 2008;52(9):3253–8. https://doi.org/10.1128/AAC.00005-08.CrossRefPubMedPubMedCentral

41.

Liu J, Miller MD, Danovich RM, Vandergrift N, Cai F, Hicks CB, et al. Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment. Antimicrob Agents Chemother. 2011;55(3):1114–9. https://doi.org/10.1128/AAC.01492-10.CrossRefPubMed

42.

Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, Perno CF. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev. 2009;11(1):17–29. https://doi.org/10.1128/AAC.01492-10.CrossRefPubMed

43.

Quashie PK, Mesplede T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol. 2012;86(5):2696–705. https://doi.org/10.1128/JVI.06591-11.CrossRefPubMedPubMedCentral

44.

Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359(4):355–65. https://doi.org/10.1056/NEJMoa0708978.CrossRefPubMed

45.

Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, D'Arrigo R, et al. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. J Infect Dis. 2012;205(4):557–67. https://doi.org/10.1093/infdis/jir821.CrossRefPubMedPubMedCentral

46.

Croxtall JD, Keam SJ. Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients. Drugs. 2009;69(8):1059–75. https://doi.org/10.2165/00003495-200969080-00007.CrossRefPubMed

47.

Stellbrink HJ. Antiviral drugs in the treatment of AIDS: what is in the pipeline ? Eur J Med Res. 2007;12(9):483–95.PubMed

48.

Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2008;82(2):764–74. https://doi.org/10.1128/JVI.01534-07.CrossRefPubMed

49.

DeJesus E, Berger D, Markowitz M, Cohen C, Hawkins T, Ruane P, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr. 2006;43(1):1–5. https://doi.org/10.1097/01.qai.0000233308.82860.2f.CrossRefPubMed

50.

Natukunda E, Gaur AH, Kosalaraksa P, Batra J, Rakhmanina N, Porter D, et al. Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial. Lancet Child Adolesc Health. 2017;1(1):27–34. https://doi.org/10.1016/S2352-4642(17)30009-3.CrossRefPubMed

51.

Savarino A. In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology. 2007;4:21. https://doi.org/10.1186/1742-4690-4-21.CrossRefPubMedPubMedCentral

52.

Margot NA, Hluhanich RM, Jones GS, Andreatta KN, Tsiang M, McColl DJ, et al. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antivir Res. 2012;93(2):288–96. https://doi.org/10.1016/j.antiviral.2011.12.008.CrossRefPubMed

53.

Kobayashi M, Nakahara K, Seki T, Miki S, Kawauchi S, Suyama A, et al. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antivir Res. 2008;80(2):213–22. https://doi.org/10.1016/j.antiviral.2008.06.012.CrossRefPubMed

54.

Garrido C, Villacian J, Zahonero N, Pattery T, Garcia F, Gutierrez F, et al. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother. 2012;56(6):2873–8. https://doi.org/10.1128/AAC.06170-11.CrossRefPubMedPubMedCentral

55.

Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother. 2008;52(4):1351–8. https://doi.org/10.1128/AAC.01228-07.CrossRefPubMedPubMedCentral

56.

Comi L, Maggiolo F. Abacavir + dolutegravir + lamivudine for the treatment of HIV. Expert Opin Pharmacother. 2016;17(15):2097–106. https://doi.org/10.1080/14656566.2016.CrossRefPubMed

57.

Hare S, Smith SJ, Metifiot M, Jaxa-Chamiec A, Pommier Y, Hughes SH, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011;80(4):565–72. https://doi.org/10.1124/mol.111.073189.CrossRefPubMedPubMedCentral

58.

Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011;55(2):813–21. https://doi.org/10.1128/AAC.01209-10.CrossRefPubMed

59.

Stellbrink HJ, Reynes J, Lazzarin A, Voronin E, Pulido F, Felizarta F, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. Aids. 2013;27(11):1771–8. https://doi.org/10.1016/S1473-3099(13)70257-3.CrossRefPubMedPubMedCentral

60.

Grant PM, Tierney C, Budhathoki C, Daar ES, Sax PE, Collier AC, et al. Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202. HIV Clin Trials. 2013;14(6):284–91.CrossRef

61.

Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361(23):2230–40. https://doi.org/10.1056/NEJMoa0906768.CrossRefPubMedPubMedCentral

62.

Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210(3):354–62. https://doi.org/10.1093/infdis/jiu051.CrossRefPubMedPubMedCentral

63.

Molina JM, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015;2(4):e127–36. https://doi.org/10.1016/S2352-3018(15)00027-2.CrossRefPubMed

64.

Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11):927–35. https://doi.org/10.1016/S1473-3099(13)70257-3.CrossRefPubMed

65.

Elliot E, Amara A, Jackson A, Moyle G, Else L, Khoo S, et al. Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. J Antimicrob Chemother. 2016;71(4):1031–6. https://doi.org/10.1093/jac/dkv425.CrossRefPubMed

66.

Shah BM, Schafer JJ, Desimone JA Jr. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV. Pharmacotherapy. 2014;34(5):506–20. https://doi.org/10.1002/phar.1386.CrossRefPubMed

67.

Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382(9893):700–8. https://doi.org/10.1016/S0140-6736(13)61221-0.CrossRefPubMed

68.

Pham HT, Labrie L, Wijting IEA, Hassounah S, Lok KY, Portna I, et al. The S230R Integrase substitution associated with virus load rebound during Dolutegravir Monotherapy confers low-level resistance to Integrase Strand-transfer inhibitors. J Infect Dis. 2018;218(5):698–706. https://doi.org/10.1093/infdis/jiy175.CrossRefPubMedPubMedCentral

69.

Wijting I, Rokx C, Boucher C, van Kampen J, Pas S, de Vries-Sluijs T, et al. Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. Lancet HIV. 2017;4(12):e547–e54. https://doi.org/10.1016/S2352-3018(17)30152-2.CrossRefPubMed

70.

Wijting IEA, Lungu C, Rijnders BJA, van der Ende ME, Pham HT, Mesplede T, et al. HIV-1 resistance dynamics in patients with Virologic failure to Dolutegravir maintenance Monotherapy. J Infect Dis. 2018;218(5):688–97. https://doi.org/10.1093/infdis/jiy176.CrossRefPubMed

71.

•• Malet I, Subra F, Charpentier C, Collin G, Descamps D, Calvez V, et al. Mutations located outside the Integrase gene can confer resistance to HIV-1 Integrase Strand transfer inhibitors. MBio. 2017;8(5). https://doi.org/10.1128/mBio.00922-17. This report is an alarming signal showing that a mutation that occurred outside the integrase gene can also contribute to the resistance to INSTIs.

72.

Van Duyne R, Kuo LS, Pham P, Fujii K, Freed EO. Mutations in the HIV-1 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication cycle. Proc Natl Acad Sci U S A. 2019;116(18):9040–9. https://doi.org/10.1073/pnas.1820333116.CrossRefPubMedPubMedCentral

73.

Zash R, Makhema J, Shapiro RL. Neural-tube defects with Dolutegravir treatment from the time of conception. N Engl J Med. 2018;379(10):979–81. https://doi.org/10.1056/NEJMc1807653.CrossRefPubMedPubMedCentral

74.

Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, et al. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet HIV. 2017;4(4):e154–e60. https://doi.org/10.1016/S2352-3018(17)30016-4.CrossRefPubMed

75.

Hassounah SA, Alikhani A, Oliveira M, Bharaj S, Ibanescu RI, Osman N, et al. Antiviral activity of bictegravir and cabotegravir against integrase inhibitor-resistant SIVmac239 and HIV-1. Antimicrob Agents Chemother. 2017;61(12). https://doi.org/10.1128/AAC.01695-17.

76.

Smith SJ, Zhao XZ, Burke TR Jr, Hughes SH. Efficacies of cabotegravir and bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology. 2018;15(1):37. https://doi.org/10.1186/s12977-018-0420-7.CrossRefPubMedPubMedCentral

77.

Tsiang M, Jones GS, Goldsmith J, Mulato A, Hansen D, Kan E, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother. 2016;60(12):7086–97. https://doi.org/10.1128/AAC.01474-16.CrossRefPubMedPubMedCentral

78.

Anstett K, Brenner B, Mesplede T, Wainberg MA. HIV drug resistance against strand transfer integrase inhibitors. Retrovirology. 2017;14(1):36. https://doi.org/10.1186/s12977-017-0360-7.CrossRefPubMedPubMedCentral

79.

Zhou T, Su H, Dash P, Lin Z, Dyavar Shetty BL, Kocher T, et al. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials. 2018;151:53–65. https://doi.org/10.1016/j.biomaterials.2017.10.023.CrossRefPubMed

80.

Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4(8):e331–e40. https://doi.org/10.1016/S2352-3018(17)30068-1.CrossRefPubMed

81.

Yoshinaga T, Kobayashi M, Seki T, Miki S, Wakasa-Morimoto C, Suyama-Kagitani A, et al. Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. Antimicrob Agents Chemother. 2015;59(1):397–406. https://doi.org/10.1128/AAC.03909-14.CrossRefPubMed

82.

Rusconi S, Marcotullio S, Cingolani A. Long-acting agents for HIV infection: biological aspects, role in treatment and prevention, and patient's perspective. New Microbiol. 2017;40(2):75–9.PubMed

83.

Margolis DA, Brinson CC, Smith GHR, de Vente J, Hagins DP, Eron JJ, et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015;15(10):1145–55. https://doi.org/10.1016/S1473-3099(15)00152-8.CrossRefPubMed

84.

Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, Podzamczer D, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499–510. https://doi.org/10.1016/S0140-6736(17)31917-7.CrossRefPubMed

85.

Whitfield T, Torkington A, van Halsema C. Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date. HIV AIDS (Auckl). 2016;8:157–64.

86.

Radzio-Basu J, Council O, Cong ME, Ruone S, Newton A, Wei X, et al. Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection. Nat Commun. 2019;10(1):2005. https://doi.org/10.1038/s41467-019-10047-w.CrossRefPubMedPubMedCentral

87.

Korolev SP, Agapkina YY, Gottikh MB. Clinical use of inhibitors of HIV-1 integration: problems and prospects. Acta Nat. 2011;3(3):12–28.CrossRef

88.

Langley DR, Samanta HK, Lin Z, Walker MA, Krystal MR, Dicker IB. The terminal (catalytic) adenosine of the HIV LTR controls the kinetics of binding and dissociation of HIV integrase strand transfer inhibitors. Biochemistry. 2008;47(51):13481–8. https://doi.org/10.1021/bi801372d.CrossRefPubMed

89.

Smith SJ, Zhao XZ, Burke TR Jr, Hughes SH. HIV-1 integrase inhibitors that are broadly effective against drug-resistant mutants. Antimicrob Agents Chemother. 2018;62(9). https://doi.org/10.1128/AAC.01035-18.

90.

Dicker IB, Samanta HK, Li Z, Hong Y, Tian Y, Banville J, et al. Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors. J Biol Chem. 2007;282(43):31186–96. https://doi.org/10.1074/jbc.M704935200.CrossRefPubMed

91.

Naidu BN, Walker MA, Sorenson ME, Ueda Y, Matiskella JD, Connolly TP, et al. The discovery and preclinical evaluation of BMS-707035, a potent HIV-1 integrase strand transfer inhibitor. Bioorg Med Chem Lett. 2018;28(12):2124–30. https://doi.org/10.1016/j.bmcl.2018.05.027.CrossRefPubMed

92.

Hoesley CJ, Chen BA, Anderson PL, Dezzutti CS, Strizki J, Sprinkle C, et al. Phase 1 safety and pharmacokinetics study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal rings. Clin Infect Dis. 2019;68(7):1136–43. https://doi.org/10.1093/cid/ciy653.CrossRefPubMed

93.

Hare S, Vos AM, Clayton RF, Thuring JW, Cummings MD, Cherepanov P. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A. 2010;107(46):20057–62. https://doi.org/10.1073/pnas.1010246107.CrossRefPubMedPubMedCentral

94.

Scopelliti F, Pollicita M, Ceccherini-Silberstein F, Di Santo F, Surdo M, Aquaro S, et al. Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes. Antivir Res. 2011;92(2):255–61. https://doi.org/10.1016/j.antiviral.2011.08.008.CrossRefPubMed

95.

Bar-Magen T, Sloan RD, Donahue DA, Kuhl BD, Zabeida A, Xu H, et al. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol. 2010;84(18):9210–6. https://doi.org/10.1128/JVI.01164-10.CrossRefPubMedPubMedCentral

96.

Van Wesenbeeck L, Rondelez E, Feyaerts M, Verheyen A, Van der Borght K, Smits V, et al. Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates. Antimicrob Agents Chemother. 2011;55(1):321–5. https://doi.org/10.1128/AAC.01733-09.CrossRefPubMed

97.

Fader LD, Malenfant E, Parisien M, Carson R, Bilodeau F, Landry S, et al. Discovery of BI 224436, a noncatalytic site Integrase inhibitor (NCINI) of HIV-1. ACS Med Chem Lett. 2014;5(4):422–7. https://doi.org/10.1021/ml500002n.CrossRefPubMedPubMedCentral

98.

Fenwick C, Amad M, Bailey MD, Bethell R, Bos M, Bonneau P, et al. Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor. Antimicrob Agents Chemother. 2014;58(6):3233–44. https://doi.org/10.1128/AAC.02719-13.CrossRefPubMedPubMedCentral

99.

Kaushik A, Jayant RD, Nair M. Advancements in nano-enabled therapeutics for neuroHIV management. Int J Nanomedicine. 2016;11:4317–25. https://doi.org/10.2147/IJN.S109943.CrossRefPubMedPubMedCentral

100.

Li W, Gorantla S, Gendelman HE, Poluektova LY. Systemic HIV-1 infection produces a unique glial footprint in humanized mouse brains. Dis Model Mech. 2017;10(12):1489–502. https://doi.org/10.1242/dmm.031773.CrossRefPubMedPubMedCentral

101.

• Montenegro-Burke JR, Woldstad CJ, Fang M, Bade AN, McMillan J, Edagwa B, et al. Nanoformulated antiretroviral therapy attenuates brain metabolic oxidative stress. Mol Neurobiol. 2019;56(4):2896–907. https://doi.org/10.1007/s12035-018-1273-8. Interesting discovery that highlights the critical importance of formulation design by convincingly demonstrating the metabolic stress in rodent brain upon administration of nano-DTG as compared to the native drug treatment.CrossRefPubMed

102.

Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014;13(9):655–72. https://doi.org/10.1038/nrd4363.CrossRefPubMedPubMedCentral

103.

Kevadiya BD, Woldstad C, Ottemann BM, Dash P, Sajja BR, Lamberty B, et al. Multimodal theranostic nanoformulations permit magnetic resonance bioimaging of antiretroviral drug particle tissue-cell biodistribution. Theranostics. 2018;8(1):256–76. https://doi.org/10.7150/thno.22764.CrossRefPubMedPubMedCentral

104.

Roy U, Drozd V, Durygin A, Rodriguez J, Barber P, Atluri V, et al. Characterization of nanodiamond-based anti-HIV drug delivery to the brain. Sci Rep. 2018;8(1):1603. https://doi.org/10.1038/s41598-017-16703-9.CrossRefPubMedPubMedCentral

105.

McMillan J, Szlachetka A, Slack L, Sillman B, Lamberty B, Morsey B, et al. Pharmacokinetics of a long-acting nanoformulated dolutegravir prodrug in rhesus macaques. Antimicrob Agents Chemother. 2018;62(1). https://doi.org/10.1128/AAC.01316-17.

106.

•• Dash PK, Kaminski R, Bella R, Su H, Mathews S, Ahooyi TM, et al. Sequential LASER ART and CRISPR treatments eliminate HIV-1 in a subset of infected humanized mice. Nat Commun. 2019;10(1):2753. https://doi.org/10.1038/s41467-019-10366-y. Excellent first ever report that demonstrates elimination of latent HIV-1 proviral reservoirs from humanized mice. CrossRefPubMedPubMedCentral

107.

McMillan J, Szlachetka A, Zhou T, Morsey B, Lamberty B, Callen S, et al. Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques. Aids. 2019;33(3):585–8. https://doi.org/10.1097/QAD.0000000000002032.CrossRefPubMed

108.

•• Sillman B, Bade AN, Dash PK, Bhargavan B, Kocher T, Mathews S, et al. Creation of a long-acting nanoformulated dolutegravir. Nat Commun. 2018;9(1):443. https://doi.org/10.1038/s41467-018-02885-x. Excellent first report of nano-formulated DTG with hydrophobic and lipophilic modifications in DTG prodrug. CrossRefPubMedPubMedCentral

109.

Tang J, Vernekar SKV, Chen YL, Miller L, Huber AD, Myshakina N, et al. Synthesis, biological evaluation and molecular modeling of 2-Hydroxyisoquinoline-1,3-dione analogues as inhibitors of HIV reverse transcriptase associated ribonuclease H and polymerase. Eur J Med Chem. 2017;133:85–96. https://doi.org/10.1016/j.ejmech.2017.03.059.CrossRefPubMedPubMedCentral

110.

Wang Z, Bennett EM, Wilson DJ, Salomon C, Vince R. Rationally designed dual inhibitors of HIV reverse transcriptase and integrase. J Med Chem. 2007;50(15):3416–9. https://doi.org/10.1021/jm070512p.CrossRefPubMed

111.

Rogolino D, Carcelli M, Compari C, De Luca L, Ferro S, Fisicaro E, et al. Diketoacid chelating ligands as dual inhibitors of HIV-1 integration process. Eur J Med Chem. 2014;78:425–30. https://doi.org/10.1016/j.ejmech.2014.03.070.CrossRefPubMed

112.

•• Singh K, Sarafianos SG, Sonnerborg A. Long-acting anti-HIV drugs targeting HIV-1 reverse transcriptase and Integrase. Pharmaceuticals (Basel). 2019;12(2). https://doi.org/10.3390/ph12020062. Excellent detailed information provided on long acting forms of RT and IN inhibitors that are at various stages of clinical trials. CrossRef

Titel: Recent Advances in the Development of Integrase Inhibitors for HIV Treatment
verfasst von: Jay Trivedi
Dinesh Mahajan
Russell J. Jaffe
Arpan Acharya
Debashis Mitra
Siddappa N. Byrareddy
Publikationsdatum: 01.02.2020
Verlag: Springer US
Erschienen in: Current HIV/AIDS Reports / Ausgabe 1/2020
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-019-00480-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

GLP-1-Rezeptoragonisten und SGLT-2-Hemmer: zusammen besser

06.05.2024 Typ-2-Diabetes Nachrichten

Immer häufiger wird ein Typ-2-Diabetes sowohl mit einem GLP-1-Rezeptor-Agonisten als auch mit einem SGLT-2-Inhibitor behandelt. Wie sich das verglichen mit den Einzeltherapien auf kardiovaskuläre und renale Komplikationen auswirkt, wurde anhand von Praxisdaten aus Großbritannien untersucht.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Purpose of the Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Bone Update: Is It Still an Issue Without Tenofovir Disoproxil Fumarate?

Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies

Optimizing Treatment for Adults with HIV/AIDS in China: Successes over Two Decades and Remaining Challenges

Addressing Minority Stress and Mental Health among Men Who Have Sex with Men (MSM) in China